Leishmaniasis is a parasitic disease caused by protozoans of the Leishmania genus, which are transmitted by infected phlebotomine sand flies. Depending on the parasite subtype and the strength of the host's immune system, the disease manifests in a cutaneous or visceral form. Cutaneous leishmaniasis is characterized by skin ulcers. The most important clinical manifestation of visceral leishmaniasis is kala-azar (Hindi for “black fever”), which presents with fever, weight loss, hepatosplenomegaly, and immunosuppression. Leishmaniasis is diagnosed by microscopic visualization of macrophages containing amastigotes in blood smears or tissue. Local treatment (cryotherapy, topical paromomycin) suffices for most cases of cutaneous leishmaniasis. Visceral leishmaniasis requires systemic treatment with amphotericin B.
- Distribution: endemic in the Mediterranean region, Africa, India, southwest and central Asia, South and Central America
- Visceral: 50,000– 90,000 infections/year
- Cutaneous: 600,000–1,000,000 infections/year
Epidemiological data refers to the US, unless otherwise specified.
- Pathogen: Leishmania donovani (protozoan) 
- Vector: phlebotomine sandflies
- Reservoir: mammals (especially dogs, humans, and rodents)
Clinical features 
- Localized cutaneous leishmaniasis
- Mucosal leishmaniasis
- Detection of the pathogen in skin biopsy
The objective of treatment is to manage clinical symptoms.
- Uncomplicated disease (no immunosuppression, small lesions, no mucosal involvement)
Complicated disease (mucosal involvement, numerous lesions, immunosuppression)
- See treatment of visceral leishmaniasis
Clinical features 
- Incubation period: 2–6 months
- Many patients are asymptomatic.
- Kala-azar (Hindi for “black fever,” in reference to the darkening of the skin it can cause)
- Laboratory tests
- Detection of pathogen
- Amphotericin B is the preferred monotherapy in Europe, North America, and South America.
- Other drugs that may be used include:
- Sodium stibogluconate
Kala-azar is highly fatal without treatment!